Literature DB >> 22079415

Bone tissue and muscle dystrophin deficiency in mdx mice.

Wilson Romero Nakagaki1, José Angelo Camilli.   

Abstract

Duchenne muscular dystrophy is a neuromuscular disease caused by the lack of dystrophin that affects skeletal muscles, causing degeneration of muscle fibers and replacing them with fibrous and adipose tissue, events that gradually lead to functional loss. Patients with Duchenne muscular dystrophy have shown that bones become more fragile with age and with advancement of the disease. Muscle weakness and reduced mobility have been suggested to be the factors that promote bone deterioration. However, it seems that this does not occur in mdx mice. It has been identified in mdx mice the existence of a factor related or not to the lack of dystrophin that also participates in the impairment of bone quality. Mdx mice also exhibit muscle degeneration, but unlike human, it is compensated by muscle regeneration. In consequence, there is an increase in the muscle mass, but not necessarily of muscle contractile strength. The accommodation of this increased muscle mass promotes bone formation at specific sites, such as at tendo-osseous junctions. In addition, the inflammatory response to muscle injury may be responsible for the increase in angiogenesis and regeneration observed in mdx mice, inducing the release of cytokines and chemokines that play an important role in the recruitment of leukocytes and macrophages. Then, mdx mice may possess compensatory mechanisms in bone in response to a genetic defect. Copyright Â
© 2011 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22079415     DOI: 10.1016/j.jbspin.2011.08.004

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  2 in total

Review 1.  Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy.

Authors:  Maria Sofia Falzarano; Chiara Passarelli; Alessandra Ferlini
Journal:  Nucleic Acid Ther       Date:  2014-02       Impact factor: 5.486

2.  Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.

Authors:  Tero Puolakkainen; Hongqian Ma; Heikki Kainulainen; Arja Pasternack; Timo Rantalainen; Olli Ritvos; Kristiina Heikinheimo; Juha J Hulmi; Riku Kiviranta
Journal:  BMC Musculoskelet Disord       Date:  2017-01-19       Impact factor: 2.362

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.